MCID: PRD006
MIFTS: 64

Prader-Willi Syndrome malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Reproductive diseases, Endocrine diseases, Fetal diseases

Aliases & Classifications for Prader-Willi Syndrome

About this section
Sources:
50OMIM, 11Disease Ontology, 69Wikipedia, 22GeneReviews, 46NIH Rare Diseases, 23GeneTests, 24Genetics Home Reference, 13DISEASES, 52Orphanet, 12diseasecard, 48Novoseek, 36MedlinePlus, 37MeSH, 25GTR, 28ICD10, 30ICD9CM, 43NCIt, 66UMLS, 29ICD10 via Orphanet, 38MESH via Orphanet, 67UMLS via Orphanet, 60SNOMED-CT, 62The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Prader-Willi Syndrome:

Name: Prader-Willi Syndrome 50 11 69 22 46 23 24 13 52 12 48 36 37
Prader-Labhart-Willi Syndrome 22 46 23 24 52
Willi-Prader Syndrome 46 24 52 25
 
Pws 22 46 23 24
Prader Willi Syndrome 11

Characteristics:

Orphanet epidemiological data:

52
prader-willi syndrome:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Antenatal,Neonatal; Age of death: normal life expectancy

HPO:

62
prader-willi syndrome:
Inheritance: sporadic


Classifications:



External Ids:

OMIM50 176270
Disease Ontology11 DOID:11983
ICD1028 Q87.1
ICD9CM30 759.81
MeSH37 D011218
SNOMED-CT60 205794007, 89392001
NCIt43 C75463
Orphanet52 ORPHA739
ICD10 via Orphanet29 Q87.1
MESH via Orphanet38 D011218
UMLS via Orphanet67 C0032897

Summaries for Prader-Willi Syndrome

About this section
MedlinePlus:36 Prader-willi syndrome (pws) is a rare genetic disorder. it causes poor muscle tone, low levels of sex hormones and a constant feeling of hunger. the part of the brain that controls feelings of fullness or hunger does not work properly in people with pws. they overeat, leading to obesity. babies with pws are usually floppy, with poor muscle tone, and have trouble sucking. boys may have undescended testicles. later, other signs appear. these include short stature poor motor skills weight gain underdeveloped sex organs mild intellectual and learning disabilities there is no cure for pws. growth hormone, exercise, and dietary supervision can help build muscle mass and control weight. other treatments may include sex hormones and behavior therapy. most people with pws will need specialized care and supervision throughout their lives. nih: national institute of child health and human development

MalaCards based summary: Prader-Willi Syndrome, also known as prader-labhart-willi syndrome, is related to prader-willi syndrome due to imprinting mutation and obesity, and has symptoms including hypogonadotrophic hypogonadism, delayed speech and language development and infertility. An important gene associated with Prader-Willi Syndrome is NDN (Necdin, MAGE Family Member), and among its related pathways are Synaptic Neurotransmission Pathways: GABAergic Inhibition and Gastric cancer network 2. Affiliated tissues include skin, brain and testes, and related mouse phenotypes are adipose tissue and behavior/neurological.

Genetics Home Reference:24 Prader-Willi syndrome is a complex genetic condition that affects many parts of the body. In infancy, this condition is characterized by weak muscle tone (hypotonia), feeding difficulties, poor growth, and delayed development. Beginning in childhood, affected individuals develop an insatiable appetite, which leads to chronic overeating (hyperphagia) and obesity. Some people with Prader-Willi syndrome, particularly those with obesity, also develop type 2 diabetes mellitus (the most common form of diabetes).

NIH Rare Diseases:46 Prader-willi syndrome (pws) is a genetic condition that affects many parts of the body. infants with pws have severe hypotonia (low muscle tone), feeding difficulties, and slow growth. in later infancy or early childhood, affected children typically begin to eat excessively and become obese. other signs and symptoms often include short stature, hypogonadism, developmental delays, cognitive impairment, and distinctive behavioral characteristics such as temper tantrums, stubbornness, and obsessive-compulsive tendencies. pws is caused by missing or non-working genes on chromosome 15. most cases are not inherited and occur randomly. rarely, a genetic change responsible for pws can be inherited. management of pws generally depends on the affected person's age and symptoms. last updated: 7/7/2016

OMIM:50 Prader-Willi syndrome is characterized by diminished fetal activity, obesity, muscular hypotonia, mental retardation,... (176270) more...

Wikipedia:69 Prader–Willi syndrome (PWS) is a genetic disorder due to loss of function of specific genes on... more...

GeneReviews summary for NBK1330

Related Diseases for Prader-Willi Syndrome

About this section

Diseases in the Prader-Willi Syndrome family:

Prader-Willi Syndrome Due to Paternal Deletion of 15q11q13 Type 1 Prader-Willi Syndrome Due to Paternal Deletion of 15q11q13 Type 2
Prader-Willi Syndrome Due to Translocation Prader-Willi Syndrome Due to Imprinting Mutation
Prader-Willi-Like Syndrome Due to Point Mutation Prader-Willi Syndrome Due to Paternal 15q11q13 Deletion
Prader-Willi Syndrome Due to Maternal Uniparental Disomy of Chromosome 15

Diseases related to Prader-Willi Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 119)
idRelated DiseaseScoreTop Affiliating Genes
1prader-willi syndrome due to imprinting mutation34.5MAGEL2, NDN, SNRPN
2obesity30.5GHRL, HCRT, IGF1, LEP, MAGEL2, PYY
3angelman syndrome25.5GABRA5, GABRB3, GH1, GHRL, HCRT, IGF1
4prader-willi syndrome due to paternal deletion of 15q11q13 type 112.2
5prader-willi syndrome due to paternal deletion of 15q11q13 type 212.2
6prader-willi syndrome due to translocation12.2
7prader-willi syndrome due to paternal 15q11q13 deletion12.2
8prader-willi syndrome due to maternal uniparental disomy of chromosome 1512.2
9schaaf-yang syndrome11.6
10myopathic intestinal pseudoobstruction10.8MAGEL2, NDN, SNRPN
11antenatal multiminicore disease with arthrogryposis multiplex congenita10.8MAGEL2, NDN, SNRPN
12glycogen storage disease due to glucose-6-phosphatase deficiency10.7MAGEL2, NDN, SNRPN
13proton-pump inhibitor-responsive esophageal eosinophilia10.7SNRPN, UBE3A
14scoliosis10.6
15hypotonia10.6
16severe hemophilia b10.5IGF1, MKRN3
17prostate cancer10.5
18morbid obesity10.5
19cetp-related hyperalphalipoproteinemia10.5IGF1, MKRN3
20neuronitis10.5
21hypogonadism10.5
22sleep disorder10.5
23dysthymic disorder10.4GHRL, LEP, PYY
24autism spectrum disorder10.4
25lymphosarcoma10.4GHRL, LEP, PYY
26gestational choriocarcinoma10.4GHRL, IGF1, LEP
27mucolipidoses10.4GHRL, LEP, PYY
28sleep apnea10.4
29growth hormone deficiency10.4
30reardon wilson cavanagh syndrome10.4IGF1, LEP
31prader-willi habitus, osteopenia, and camptodactyly10.3
32alveoli adenoma10.3GHRL, IGF1, LEP
33obstructive sleep apnea10.3
34down syndrome10.3
35epilepsy10.3
36thyroiditis10.3
37hypersomnia10.3
38dyserythropoietic anemia, congenital, type iii10.3NPAP1, UBE3A
39survival motor neuron spinal muscular atrophy10.3GHRL, IGF1, LEP
40fragile x syndrome10.3
41cerebritis10.3
42precocious puberty10.3
43mosaic trisomy 1510.3
44protein s deficiency10.3GH1, GHRL, IGF1
45growth hormone insensitivity, partial10.2GH1, IGF1
46insulin-like growth factor i10.2
47glomerulonephritis10.2
48oculocutaneous albinism10.2
49panniculitis10.2
50polyhydramnios10.2

Graphical network of the top 20 diseases related to Prader-Willi Syndrome:



Diseases related to prader-willi syndrome

Symptoms for Prader-Willi Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

176270

Clinical features from OMIM:

176270

Symptoms:

 52 (show all 30)
  • cryptorchidism
  • hypogonadotrophic hypogonadism
  • high palate
  • microcephaly
  • strabismus
  • downslanted palpebral fissures
  • telecanthus
  • abnormality of dental enamel
  • behavioral abnormality
  • brachydactyly syndrome
  • intellectual disability
  • seizures
  • ataxia
  • muscular hypotonia
  • global developmental delay
  • specific learning disability
  • intrauterine growth retardation
  • obesity
  • scoliosis
  • downturned corners of mouth
  • delayed skeletal maturation
  • clinodactyly of the 5th finger
  • short palm
  • short stature
  • bilateral single transverse palmar creases
  • hypoplasia of penis
  • abnormal hair pattern
  • type i diabetes mellitus
  • hypoplasia of the ear cartilage
  • glomerulopathy

HPO human phenotypes related to Prader-Willi Syndrome:

(show all 99)
id Description Frequency HPO Source Accession
1 hypogonadotrophic hypogonadism hallmark (90%) HP:0000044
2 delayed speech and language development hallmark (90%) HP:0000750
3 infertility hallmark (90%) HP:0000789
4 growth hormone deficiency hallmark (90%) HP:0000824
5 global developmental delay hallmark (90%) HP:0001263
6 motor delay hallmark (90%) HP:0001270
7 generalized hypotonia hallmark (90%) HP:0001290
8 specific learning disability hallmark (90%) HP:0001328
9 obesity hallmark (90%) HP:0001513
10 failure to thrive in infancy hallmark (90%) HP:0001531
11 short foot hallmark (90%) HP:0001773
12 poor suck hallmark (90%) HP:0002033
13 polyphagia hallmark (90%) HP:0002591
14 short palm hallmark (90%) HP:0004279
15 narrow palm hallmark (90%) HP:0004283
16 short stature hallmark (90%) HP:0004322
17 cryptorchidism 85% HP:0000028
18 attention deficit hyperactivity disorder common (75%) HP:0007018
19 scrotal hypoplasia 69% HP:0000046
20 adrenal insufficiency 60% HP:0000846
21 primary amenorrhea 56% HP:0000786
22 micropenis typical (50%) HP:0000054
23 clitoral hypoplasia typical (50%) HP:0000060
24 hypoplastic labia minora typical (50%) HP:0000064
25 thin upper lip vermilion typical (50%) HP:0000219
26 narrow forehead typical (50%) HP:0000341
27 narrow nasal bridge typical (50%) HP:0000446
28 delayed puberty typical (50%) HP:0000823
29 cutaneous photosensitivity typical (50%) HP:0000992
30 nasal speech typical (50%) HP:0001611
31 recurrent respiratory infections typical (50%) HP:0002205
32 scoliosis typical (50%) HP:0002650
33 downturned corners of mouth typical (50%) HP:0002714
34 kyphosis typical (50%) HP:0002808
35 decreased muscle mass typical (50%) HP:0003199
36 almond-shaped palpebral fissure typical (50%) HP:0007874
37 sleep apnea typical (50%) HP:0010535
38 cryptorchidism typical (50%) HP:0000028
39 abnormality of the palate typical (50%) HP:0000174
40 microcephaly typical (50%) HP:0000252
41 strabismus typical (50%) HP:0000486
42 downslanted palpebral fissures typical (50%) HP:0000494
43 telecanthus typical (50%) HP:0000506
44 abnormality of dental enamel typical (50%) HP:0000682
45 behavioral abnormality typical (50%) HP:0000708
46 single transverse palmar crease typical (50%) HP:0000954
47 brachydactyly syndrome typical (50%) HP:0001156
48 seizures typical (50%) HP:0001250
49 muscular hypotonia typical (50%) HP:0001252
50 intrauterine growth retardation typical (50%) HP:0001511
51 obesity typical (50%) HP:0001513
52 incoordination typical (50%) HP:0002311
53 delayed skeletal maturation typical (50%) HP:0002750
54 abnormality of chromosome segregation typical (50%) HP:0002916
55 clinodactyly of the 5th finger typical (50%) HP:0004209
56 short stature typical (50%) HP:0004322
57 hypoplasia of penis typical (50%) HP:0008736
58 cognitive impairment typical (50%) HP:0100543
59 type i diabetes mellitus typical (50%) HP:0100651
60 hypoplasia of the ear cartilage typical (50%) HP:0100720
61 glomerulopathy typical (50%) HP:0100820
62 oligomenorrhea frequent (33%) HP:0000876
63 hypopigmentation of the skin frequent (33%) HP:0001010
64 ventriculomegaly frequent (33%) HP:0002119
65 hypopigmentation of hair frequent (33%) HP:0005599
66 impaired pain sensation frequent (33%) HP:0007328
67 iris hypopigmentation frequent (33%) HP:0007730
68 type ii diabetes mellitus 25% HP:0005978
69 autism 19% HP:0000717
70 psychosis 15% HP:0000709
71 seizures 15% HP:0001250
72 hip dysplasia 10% HP:0001385
73 myopia occasional (7.5%) HP:0000545
74 esotropia occasional (7.5%) HP:0000565
75 upslanted palpebral fissure occasional (7.5%) HP:0000582
76 carious teeth occasional (7.5%) HP:0000670
77 osteopenia occasional (7.5%) HP:0000938
78 osteoporosis occasional (7.5%) HP:0000939
79 syndactyly occasional (7.5%) HP:0001159
80 frontal upsweep of hair occasional (7.5%) HP:0002236
81 temperature instability occasional (7.5%) HP:0005968
82 poor fine motor coordination occasional (7.5%) HP:0007010
83 radial deviation of finger occasional (7.5%) HP:0009466
84 precocious puberty 4% HP:0000826
85 hypogonadism HP:0000135
86 intellectual disability HP:0001249
87 muscular hypotonia HP:0001252
88 truncal obesity HP:0001956
89 feeding difficulties in infancy HP:0008872
90 thin upper lip vermilion HP:0000219
91 dolichocephaly HP:0000268
92 hypermetropia HP:0000540
93 hyperinsulinemia HP:0000842
94 decreased fetal movement HP:0001558
95 hypoventilation HP:0002791
96 poor gross motor coordination HP:0007015
97 generalized hypopigmentation HP:0007513
98 abdominal obesity HP:0012743
99 clinodactyly HP:0030084

Drugs & Therapeutics for Prader-Willi Syndrome

About this section

Drugs for Prader-Willi Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
LiraglutidePhase 4, Phase 3293204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
2
OxytocinPhase 2, Phase 3, Phase 139050-56-6439302, 53477758
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
(Arg8)-Vasopressin
(Arg8)-Vasotocin
1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide
50-56-6
AC1L9735
Argipressin
Argpressin Acetate
BCBcMAP01_000094
Biotinyl-(Arg8)-Vasopressin
C00746
CHEBI:492195
CHEBI:7872
CHEMBL395429
CID439302
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Cys-Tyr-Ile-Thr-Asn-Cys-Gly-Leu-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
D00089
Disulfide bridge Cys1-Cys6
Gly-Leu-Pro-c
HS-2021
 
L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide
MolPort-003-938-941
NCGC00167132-01
O3251_SIGMA
O4375_SIGMA
OXT
OXYTOCIN
Ocytocin
Oxitocina
Oxytocic hormone
Oxytocin (JP15/USP/INN)
Oxytocin (TN)
Oxytocin 10 Usp Units In Dextrose 5%
Oxytocin 20 Usp Units In Dextrose 5%
Oxytocin 5 Usp Units In Dextrose 5%
Oxytocin Acetate
Oxytocin injection
Oxytocine
Oxytocinum
Pitocin
Pitocin (TN)
Syntocinon
Syntocinon (TN)
TI-001
alpha-Hypophamine
nchembio.184-comp2
3
TopiramatePhase 324497240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
 
Ortho brand of topiramate
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]
4
OctreotidePhase 320683150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
5
RimonabantPhase 345168273-06-1, 158681-13-1104850
Synonyms:
168273-06-1
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide
5-(p-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide
A 281
AC-163720
AC-731
AC1L2XM5
Acomplia
Acomplia (TN)
C14319
CHEMBL111
CID104850
D05731
DB06155
I06-0381
L000572
LS-128155
 
MolPort-003-850-185
NCGC00164572-01
Rimonabant
Rimonabant (JAN/USAN/INN)
Rimonabant [USAN:INN]
Rimoslim
Riobant
SR 141716
SR 141716A
SR-141716
SR-141716A
SR141,716A
SR141716
SR141716A
STK642500
Slimona
UNII-RML78EN3XE
ZINC01540228
[3H]SR141716A
nchembio.129-comp21
nchembio.552-comp16
6
SomatostatinPhase 321238916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
7
DiazoxidePhase 1, Phase 222364-98-73019
Synonyms:
2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
364-98-7
7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]
7-chloro-3-methyl-4H-1
AC1L1EZN
Aroglycem
BPBio1_000016
BRD-K73109821-001-05-2
BSPBio_000014
BSPBio_001307
BSPBio_002290
Bio1_000036
Bio1_000525
Bio1_001014
Bio2_000027
Bio2_000507
C06949
C8H7ClN2O2S
CAS-364-98-7
CBiol_001750
CHEBI:4495
CHEMBL181
CID3019
CPD000058392
D 9035
D00294
D003981
D9035_SIGMA
DB01119
Diazossido
Diazossido [DCIT]
Diazossido [Italian]
Diazoxide
Diazoxide (JAN/USP/INN)
Diazoxide [USAN:INN:BAN]
Diazoxido
Diazoxido [INN-Spanish]
Diazoxidum
Diazoxidum [INN-Latin]
Dizoxide
EINECS 206-668-1
EU-0100404
Eudemine
HMS1361B09
HMS1568A16
HMS1791B09
HMS1922L22
HMS1989B09
HMS2051P20
HMS2089L04
HMS2093N12
Hyperstat
Hyperstat (TN)
Hypertonalum
I06-2041
 
IDI1_033777
KBio2_000027
KBio2_002595
KBio2_005163
KBio3_000053
KBio3_000054
KBio3_001510
KBioGR_000027
KBioGR_001776
KBioSS_000027
LS-40410
Lopac-D-9035
Lopac0_000404
MLS000028459
MLS001076071
MolPort-003-666-772
MolPort-003-941-186
Mutabase
NCGC00015380-01
NCGC00015380-02
NCGC00015380-03
NCGC00015380-05
NCGC00015380-12
NCGC00024907-01
NCGC00024907-02
NCGC00024907-03
NCGC00024907-04
NCGC00024907-05
NCGC00024907-06
NCGC00024907-07
NCGC00024907-08
NSC 64198
NSC 76130
NSC-64198
NSC64198
NSC76130
Prestwick0_000087
Prestwick1_000087
Prestwick2_000087
Prestwick3_000087
Prestwick_163
Proglicem
Proglycem
SAM001246872
SMR000058392
SPBio_001953
SPECTRUM2300206
SRG 95213
SRG-95213
Sch 6783
Sch-6783
Spectrum3_000735
Spectrum4_001248
Tocris-0964
UNII-O5CB12L4FN
VU0239714-6
ZINC03872277
diazoxide
nchembio.150-comp49
nchembio.476-comp10
8methionineNutraceuticalPhase 276
9
CholineNutraceuticalPhase 1, Phase 214762-49-7305
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(beta-hydroxyethyl)trimethylammonium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
2-Hydroxy-N,N,N-trimethylethanaminium
Bilineurine
Biocolina
Biocoline
Choline
Choline cation
 
Choline ion
Cholinum
Hepacholine
Hormocline
Lipotril
N,N,N-Trimethylethanol-ammonium
N,N,N-Trimethylethanolammonium
N,N,N-trimethylethanol-ammonium
N-trimethylethanolamine
Neocolina
Paresan
trimethylethanolamine
10insulin4401
11
Hydrocortisone60250-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
12
Exenatide281141758-74-915991534
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC-2993
AC002993
AC2993
AC2993a
Bydureon
Byetta
 
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide Synthetic
Exenatide synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
13
Metyrapone1254-36-44174
Synonyms:
1,2-Di-3-pyridyl-2-methyl-1-propanone
2-Methyl-1,2-bis(3-pyridyl)-1-propanone
2-Methyl-1,2-di-3-pyridinyl-1-propanone
2-Methyl-1,2-di-3-pyridyl-1-propanone
2-methyl-1,2-dipyridin-3-yl-propan-1-one
2-methyl-1,2-dipyridin-3-ylpropan-1-one
37245-80-0
4885, SU
54-36-4
856525_ALDRICH
AB00513955
AC1L1HKV
AC1Q1LHX
Alliance Brand of Metyrapone
BIDD:PXR0082
BPBio1_000824
BRD-K46862739-001-03-6
BSPBio_000748
C07205
C14H14N2O
CAS-54-36-4
CHEBI:44241
CHEMBL934
CID4174
CPD-7023
CPD000059134
D00410
D008797
DB01011
EINECS 200-206-2
EU-0009322
HMS1570F10
HMS2094I07
HSDB 2500
LS-123097
METOPIRONE (TN)
MLS001066377
MLS001335881
MLS001335882
MYT
 
Mepyrapone
Metapirone
Metapyron
Methapyrapone
Methbipyranone
Methopirapone
Methopyrapone
Methopyrinine
Methopyrone
Metirapona
Metirapona [INN-Spanish]
Metopiron
Metopirone
Metopyrone
Metroprione
Metyrapon
Metyrapone
Metyrapone (JP15/USP/INN)
Metyrapone Alliance Brand
Metyrapone Novartis Brand
Metyrapone [USAN:INN:BAN:JAN]
Metyraponum
Metyraponum [INN-Latin]
MolPort-001-794-644
NCGC00016242-01
NCGC00161837-01
NSC 25265
NSC25265
Novartis Brand of Metyrapone
Prestwick0_000904
Prestwick1_000904
Prestwick2_000904
Prestwick3_000904
SAM002297829
SMR000059134
SPBio_002947
ST51006925
Su 4885
Su-4885
UNII-ZS9KD92H6V
ZINC00001728
metyrapone
14
Cosyntropin2516960-16-016129617
Synonyms:
16960-16-0
ATCH (1-24)
Adrenocorticotropic hormone 1-24
COSYNTROPIN
Corticotropin-(1-24)
Corticotropin-(1-24) tetracosapeptide
Cortrosyn
Cortrosyn (TN)
 
Cosyntropin
Cosyntropin (USAN)
D00284
SYSMEHFRWGKPVGKKRRPVKVYP
SerTyrSerMetGluHisPheArgTrpGlyLysProValGlyLysLysArgArgProValLysValTyrPro
Tetracosactide
Tetracosactide (INN)
alpha(1-24)-Corticotrophin
beta(1-24)-Corticotrophin
15
Epinephrine88651-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
16
Anastrozole266120511-73-12187
Synonyms:
.alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
1,3-benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)
120511-73-1
2,2'-(5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene)bis(2-methylpropionitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)
2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
AC-4234
AC1L1D49
Anastrazole
Anastrole
Anastrozol
Anastrozole (JAN/USAN/INN)
Anastrozole [USAN:INN:BAN]
Arimidex
Arimidex (TN)
Arimidex (Zeneca)
Arimidex, Anastrozole
Asiolex
Astra brand of anastrozole
AstraZeneca brand of anastrozole
C08159
C090450
C17H19N5
CHEBI:2704
CHEMBL1399
CID2187
CPD000466301
 
D00960
DB01217
HMS2052M11
HMS2089N10
HSDB 7462
I06-0021
ICI D1033
ICI-D 1033
ICI-D1033
LS-29563
MLS000759396
MLS001424217
MolPort-005-933-078
NCGC00164619-01
NSC719344
S1188_Selleck
SAM001246525
SBB066057
SMR000466301
UNII-2Z07MYW1AZ
ZD 1033
ZD-1033
ZD1033
ZINC00000941
Zeneca ZD 1033
Zeneca brand of anastrozole
alpha,alpha,Alpha',alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile
anastrazole
anastrozole
17
Menthol21842216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol

Interventional clinical trials:

(show top 50)    (show all 60)
idNameStatusNCT IDPhase
1Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?CompletedNCT01298180Phase 4
2Liraglutide Use in Prader-Willi SyndromeTerminatedNCT01542242Phase 4
3Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 WeeksCompletedNCT02810483Phase 3
4Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi SyndromeRecruitingNCT02804373Phase 2, Phase 3
5Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi SyndromeRecruitingNCT02204163Phase 3
6Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi SyndromeRecruitingNCT00603109Phase 3
7Growth Hormone Use in Adults With Prader-Willi SyndromeRecruitingNCT00444964Phase 3
8Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeRecruitingNCT02527200Phase 3
9Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi SyndromeActive, not recruitingNCT02179151Phase 3
10Prader-Willi Syndrome and AppetiteTerminatedNCT00175305Phase 3
11Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot ProjectCompletedNCT00742664Phase 1, Phase 2
12Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi SyndromeCompletedNCT02034071Phase 1, Phase 2
13Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi SyndromeCompletedNCT01968187Phase 2
14An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi SyndromeCompletedNCT01818921Phase 2
15Comparative Study Between Prader-Willi Patients Who Take Oxytocin Versus PlaceboCompletedNCT01038570Phase 2
16Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS InfantsCompletedNCT02205034Phase 1, Phase 2
17Tolerance of Intranasal Administration of OT in Prader-Willi Newborn BabiesCompletedNCT01548521Phase 1, Phase 2
18Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi SyndromeRecruitingNCT02311673Phase 2
19Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi SyndromeRecruitingNCT02629991Phase 2
20Cannabidiol Oral Solution for The Treatment of Subjects With Prader-Willi SyndromeNot yet recruitingNCT02844933Phase 2
21A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)Not yet recruitingNCT02893618Phase 2
22Oxytocin Trial in Prader-Willi SyndromeCompletedNCT02013258Phase 1
23Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult VolunteersCompletedNCT01401244Phase 1
24Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi SyndromeRecruitingNCT02297022Phase 1
25Parents Resources for Decreasing the Incidence of Change Triggered Temper OutburstsActive, not recruitingNCT02567357Phase 1
26Hypoglycemia in Prader-Willi SyndromeCompletedNCT01897363
27Characteristics of Prader-Willi Syndrome and Early-onset Morbid ObesityCompletedNCT00375089
28Treatment of Self-Injurious Behavior in Individuals With Prader-Willi SyndromeCompletedNCT00065923
29Effects of Exenatide on Overweight Adolescents With Prader-Willi SyndromeCompletedNCT01444898
30Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi SyndromeCompletedNCT01622751
31Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi SyndromeCompletedNCT01479322
32Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi SyndromeCompletedNCT00800852
33Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi SyndromeCompletedNCT00705172
34Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi SyndromeCompletedNCT00372125
35The Intestinal Function in People With Prader-Willi SyndromeCompletedNCT01523288
36Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy ControlsCompletedNCT00932932
37Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PWCompletedNCT02670694
38Correlation of Hyperghrelinemia With Carotid Artery Intima-Media Thickness in Children With Prader-Willi SyndromeCompletedNCT00474643
39Ghrelin Suppression by Octreotide in Prader-WilliCompletedNCT01613495
40Characterization of Transcriptional Regulators of Ghrelin Hormone Which Causes Genetic ObesityCompletedNCT01404624
41Macronutrient Regulation of Ghrelin and Peptide YYCompletedNCT02464514
42Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion SyndromesCompletedNCT00004351
43Brain-Derived Neurotrophic Factor in Obesity and Brain FunctionCompletedNCT01517048
44Prader-Willi Syndrome Macronutrient StudyRecruitingNCT02011360
45Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home StudyRecruitingNCT02058342
46Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi SyndromeRecruitingNCT01863017
47Register of Patients With Prader-Willi SyndromeRecruitingNCT02829684
48Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi SyndromeRecruitingNCT02368379
49Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi SyndromeRecruitingNCT00551343
50PWS European Blood Bank for Infants and Controls From 0 to 48 MonthsRecruitingNCT02529085

Search NIH Clinical Center for Prader-Willi Syndrome


Cochrane evidence based reviews: prader-willi syndrome

Genetic Tests for Prader-Willi Syndrome

About this section

Genetic tests related to Prader-Willi Syndrome:

id Genetic test Affiliating Genes
1 Prader-Willi Syndrome25 23

Anatomical Context for Prader-Willi Syndrome

About this section

MalaCards organs/tissues related to Prader-Willi Syndrome:

34
Skin, Brain, Testes, Bone, Endothelial, Pituitary, Smooth muscle

Animal Models for Prader-Willi Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Prader-Willi Syndrome:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053759.1GHRL, IGF1, LEP, MAGEL2, OXT, PYY
2MP:00053868.1GABRA5, GABRB3, GHRL, HCRT, LEP, MAGEL2
3MP:00036318.0GABRA5, GABRB3, HCRT, IGF1, LEP, MAGEL2

Publications for Prader-Willi Syndrome

About this section

Articles related to Prader-Willi Syndrome:

(show top 50)    (show all 775)
idTitleAuthorsYear
1
Baroreflex Dysfunction in Prader Willi Syndrome. (27134867)
2016
2
Autism spectrum disorder in Prader-Willi syndrome: A systematic review. (26331980)
2015
3
Psychiatric disorders in children with Prader-Willi syndrome-Results of a 2-year longitudinal study. (25712902)
2015
4
Polyhydramnios associated with Prader-Willi syndrome. (26271012)
2015
5
Genetic Differentiation of Hypothalamus Parentally Biased Transcripts in Populations of the House Mouse Implicate the Prader-Willi Syndrome Imprinted Region as a Possible Source of Behavioral Divergence. (25172960)
2014
6
The imprinted NPAP1 gene in the Prader-Willi syndrome region belongs to a POM121-related family of retrogenes. (24482533)
2014
7
Assessment of Pretend Play in Prader-Willi Syndrome: A Direct Comparison to Autism Spectrum Disorder. (25241008)
2014
8
Social and emotional processing in Prader-Willi syndrome: genetic subtype differences. (23536992)
2013
9
Divergent structural brain abnormalities between different genetic subtypes of children with Prader-Willi syndrome. (24144356)
2013
10
Impaired theory of mind and symptoms of Autism Spectrum Disorder in children with Prader-Willi syndrome. (23792373)
2013
11
The Mini-Gastric Bypass in the Management of Morbid Obesity in Prader-Willi Syndrome: A Viable Option? (24063639)
2013
12
Prader-Willi syndrome and sleep-disordered breathing. (24126982)
2013
13
Prader-Willi syndrome - care of adults in general practice. (23529462)
2013
14
Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. (23318724)
2013
15
Change in prevalence of congenital defects in children with Prader-Willi syndrome. (23296430)
2013
16
Growth hormone receptor (GHR) gene polymorphism and Prader-Willi syndrome. (23696513)
2013
17
Medical management for adults with Prader-Willi syndrome. (23869419)
2013
18
Central sleep-disordered breathing and the effects of oxygen therapy in infants with Prader-Willi syndrome. (23761691)
2013
19
Endocrine manifestations and management of Prader-Willi syndrome. (23962041)
2013
20
Laparoscopic sleeve gastrectomy in Chinese female patient with Prader-Willi syndrome and diabetes. (22951076)
2013
21
Experience of severe desaturation during anesthetic induction period in an obese adult patient with Prader-Willi syndrome -A case report-. (22379576)
2012
22
Prader-Willi syndrome in Victoria: mortality and causes of death. (22697408)
2012
23
Trajectory and outcomes of speech language therapy in the Prader-Willi syndrome (PWS): case report. (21552737)
2011
24
In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. (21722955)
2011
25
Magel2, a Prader-Willi syndrome candidate gene, modulates the activities of circadian rhythm proteins in cultured cells. (22208286)
2011
26
Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome. (21932585)
2011
27
Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome. (21664161)
2011
28
Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. (20980432)
2011
29
Normal cortisol response on low-dose synacthen (1 microg) test in children with Prader Willi syndrome. (20810574)
2010
30
Dementia in a woman with Prader-Willi syndrome. (20219703)
2010
31
Analysis of N- and O-linked protein glycosylation in children with Prader-Willi syndrome. (20825553)
2010
32
Genetic subtype differences in neural circuitry of food motivation in Prader-Willi syndrome. (19048015)
2009
33
Pituitary abnormalities in Prader-Willi syndrome and early onset morbid obesity. (17431897)
2008
34
Persistent growth failure in Prader-Willi syndrome associated with short-chain acyl-CoA dehydrogenase gene variant. (18184946)
2008
35
A mindfulness-based health wellness program for an adolescent with Prader-Willi syndrome. (18285504)
2008
36
Adrenarche in Prader-Willi syndrome appears not related to insulin sensitivity and serum adiponectin. (17085944)
2007
37
Nutrient intake and body composition variables in Prader-Willi syndrome--effect of growth hormone supplementation and genetic subtype. (17550213)
2007
38
Changing rates of genetic subtypes of Prader-Willi syndrome in the UK. (16957680)
2007
39
Changes in carbohydrate metabolism and insulin resistance in patients with Prader-Willi Syndrome (PWS) under growth hormone therapy]. (17340066)
2007
40
Prader-Willi syndrome: an update and review for the primary pediatrician. (17522286)
2007
41
Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome. (17407467)
2007
42
Partial cerebellar hypoplasia in a patient with Prader-Willi syndrome. (16801186)
2006
43
The Prader-Willi syndrome murine imprinting center is not involved in the spatio-temporal transcriptional regulation of the Necdin gene. (15634360)
2005
44
Absence of microdeletions in the Y chromosome in patients with Prader-Willi syndrome with cryptorchidism. (11869370)
2002
45
Evidence for the role of PWCR1/HBII-85 C/D box small nucleolar RNAs in Prader-Willi syndrome. (12154412)
2002
46
Assessment of SNRPN expression as a molecular tool in the diagnosis of Prader-Willi syndrome. (10229769)
1999
47
The genetic basis for Prader-Willi syndrome: the importance of imprinted genes. (9401540)
1997
48
Exclusion of SNRPN as a major determinant of Prader-Willi syndrome by a translocation breakpoint. (8630505)
1996
49
Validation studies of SNRPN methylation as a diagnostic test for Prader-Willi syndrome. (8957518)
1996
50
A genetic model for the Prader-Willi syndrome and its implication for Angelman syndrome. (1427794)
1992

Variations for Prader-Willi Syndrome

About this section

Copy number variations for Prader-Willi Syndrome from CNVD:

6 (show all 45)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137421127800000DeletionPrader-willi syndrome
289246151700000023300000Copy numberSNRPNPrader-willi syndrome
389251151700000031400000Copy numberPrader-willi syndrome
489253151700000031400000Copy numberC15orf2Prader-willi syndrome
589254151700000031400000Copy numberNDNPrader-willi syndrome
689255151700000031400000Copy numberSNORDPrader-willi syndrome
789256151700000031400000Copy numberSNRPNPrader-willi syndrome
889261151700000031400000DeletionPrader-willi syndrome
989262151700000031400000DeletionPrader-willi syndrome
1089263151700000031400000DeletionPrader-willi syndrome
1189267151700000031400000DeletionUBE3APrader-willi syndrome
1289283151700000031400000DuplicationNDNPrader-willi syndrome
1389285151700000031400000DuplicationSNRPNPrader-willi syndrome
1489286151700000031400000DuplicationSNRPNPrader-willi syndrome
1589289151700000031400000DuplicationUBE3APrader-willi syndrome
1689290151700000031400000DuplicationUBE3APrader-willi syndrome
1789292151700000031400000Genomic rearrangemen tPrader-willi syndrome
1889294151700000031400000MicrodeletionPrader-willi syndrome
1989295151700000031400000MicrodeletionPrader-willi syndrome
2089296151700000031400000MicrodeletionPrader-willi syndrome
2189298151700000031400000MicrodeletionSNRPNPrader-willi syndrome
2289413151840000023300000DeletionPrader-willi syndrome
2389434151840000031400000DeletionPrader-willi syndrome
2489562151868300027286000DeletionPrader-willi syndrome
2589763151900000033600000Copy numberPrader-willi syndrome
2690357152148164621483543Copy numberNDNPrader-willi syndrome
2790510152261988622795318Copy numberSNRPNPrader-willi syndrome
2890529152283559423010179MicrodeletionHBII-85Prader-willi syndrome
2990530152283559423010179MicrodeletionSNURFPrader-willi syndrome
3090531152283559423010179MicrodeletionSNRPNPrader-willi syndrome
3190532152283559423010179MicrodeletionUBE3APrader-willi syndrome
3290759152313348823235221Copy numberUBE3APrader-willi syndrome
3391319152900000031400000MicrodeletionCHRNA7Prader-willi syndrome
3491774153347194135072476DeletionATPBD4Prader-willi syndrome
3591775153347194135072476DeletionCSNK1A1PPrader-willi syndrome
3691776153347194135072476DeletionMEIS2Prader-willi syndrome
37112051173780000041900000LossPrader-willi syndrome
381384240152940457153016382DeletionMECP2Prader-willi syndrome
39160279221180000024300000Microdeletion or mic roduplicationPrader-willi syndrome
40161857222050000021800000LossPrader-willi syndrome
4119806251900000033600000DeletionPrader-willi syndrome
42203653612300000GainPrader-willi syndrome
4323933783850000039500000LossPrader-willi syndrome
44257160014300000LossPrader-willi syndrome
452602440146900000154913754LossPrader-willi syndrome

Expression for genes affiliated with Prader-Willi Syndrome

About this section
Search GEO for disease gene expression data for Prader-Willi Syndrome.

GO Terms for genes affiliated with Prader-Willi Syndrome

About this section

Cellular components related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GABA-A receptor complexGO:190271110.7GABRA5, GABRB3
2postsynapseGO:009879410.5GHRL, HCRT
3extracellular regionGO:00055768.8GH1, GHRL, HCRT, IGF1, LEP, OXT

Biological processes related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1bone mineralization involved in bone maturationGO:003563010.5IGF1, LEP
2inner ear receptor cell developmentGO:006011910.5GABRA5, GABRB3
3positive regulation of insulin-like growth factor receptor signaling pathwayGO:004356810.5GH1, IGF1
4innervationGO:006038410.4GABRA5, GABRB3
5positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.4GH1, IGF1
6adult feeding behaviorGO:000834310.3GHRL, LEP
7positive regulation of JAK-STAT cascadeGO:004642710.3GH1, LEP
8female pregnancyGO:00075659.9IGF1, LEP, OXT
9positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.9GH1, IGF1, LEP, UBE3A
10neuron developmentGO:00486669.9GABRA5, GABRB3, NDN
11eating behaviorGO:00427559.8HCRT, LEP, OXT, PYY
12response to activityGO:00148239.6IGF1, LEP, OXT
13response to estradiolGO:00323559.4GH1, LEP, OXT

Molecular functions related to Prader-Willi Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GABA-A receptor activityGO:000489010.5GABRA5, GABRB3
2neuropeptide hormone activityGO:00051849.7HCRT, OXT, PYY
3hormone activityGO:00051799.1GH1, GHRL, IGF1, LEP, PYY

Sources for Prader-Willi Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet